A holographic near-eye display device with multi-angle simultaneous illumination comprises a light source module, a spatial light modulator, a beam splitter, an eyepiece, and a master controller. The light source module emits parallel light at different angles and simultaneously illuminates and covers effective working area of spatial light modulator which, loaded with a hologram, modulates incident parallel light at different angles to form diffracted parallel light at different angles, that is, virtual images at different viewing angles. Parallel light at different angles illuminates spatial light modulator. After modulated and diffracted by calculated hologram on spatial light modulator, the diffracted image light is converged by second lens to form different viewpoints for human eye to view. In multi-angle simultaneous illumination, additional time-sharing control of illumination unit is not needed. When size and position of human eye pupil change, clear virtual image is always seen, achieving expanding the eyebox.
Colistin is an important last-resort antibiotic, but its production involves significant challenges due to the presence of impurities resulting from various analogs and the limited number of native producers. In response, disclosed are mutant Paenibacillus bacteria that produce Colicin A more efficiently and/or Colicin A that is of higher purity and/or has a cleaner metabolite background. The disclosed mutant bacteria are genetically engineered to inactivate expression of one or more biosynthetic gene clusters (BGCs), increase expression of one or more other BCGs, and/or increase expression of one or more L-DABA pathway genes.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora pour Bacillus
C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
Provided are compositions comprising chemically synthesized pseudaminic acid (Pse) conjugated to a carrier protein using the OPA chemistry, methods of using said compositions to stimulate immune responses in subjects and protect the vaccinated subjects from infections caused by Pse-producing A. baumannii.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/385 - Haptènes ou antigènes, liés à des supports
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
Provided are a composition comprising a peptide conjugated to a TLR agonist, including TLR7 agonist 1v209, and methods of using the composition. The methods comprise administering the peptide-based vaccine conjugate to a subject. The peptide-based vaccine conjugate inhibits tumor growth and induces antigen-specific B and T cell responses in a subject.
The present invention relates to a compound for treating fungal disease, wherein said compound provide target-specific inhibition of fungal adhesion, biofilm formation, and filamentation without affecting their growth, at very low concentration. The compound of the present invention is selected from FDA approved drugs Cangrelor. Further, the present invention provides a composition comprising compound of the present invention and a pharmaceutically acceptable carrier. Further, the present invention provides a method of treating fungal infections using the compound and/or composition of the present invention. Furthermore, uses of the compound and/or composition is also being provided in the present disclosure.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A feed composition for spray drying comprises 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), leucine, an anti-IL-4Rα antibody or an antigen binding fragment thereof, and a solvent. A method of preparing a pharmaceutical composition comprises a step of spray drying the feed composition by such as a spray dryer. A pharmaceutical composition comprises or consists of: 2HPβCD, leucine, an anti-IL-4Rα antibody or an antigen-binding fragment thereof. Use of the feed composition according to any of the pharmaceutical composition or according to any of the manufacture of a medicament for preventing or treating a disease, preferably, the disease is one that can be treated by the anti-IL-4R antibody or an antigen binding fragment thereof.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
7.
COMPOSITIONS AND METHODS FOR ENHANCING EFFICACY AND REDUCING ADVERSE EFFECTS FROM COVID VACCINATION
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
Disclosed are methods for constructing disulfide mimetics for late-stage cyclization of peptides. The disclosed method provides late-stage cyclization via thioacetalization of peptides containing two cysteine residues to form thioacetal group. These bonds are stable under acidic, basic, and reduced conditions. The reaction can use a broad range of cyclic ketones even acetone as crosslinkers. Trifluoroacetic acid (TFA) alone can act as both the catalyst and the sole solvent, thus allowing most peptide sequences to be cyclized via the disclosed method. The disclosed method provides a number of benefits and advantages, such as the use of TFA as both a robust catalyst of the reaction and the sole solvent needed, the easy availability of acetone and of diverse cyclic ketones for use as the reactant, the good chemoselectivity and tolerance of native peptide to the reaction, and the fact that the resulting crosslinks are structural mimetics of disulfides.
232222-alkyl, SCHF-alkyl, S-alkyl, S-aryl, etc., onto tryptophan residue (s) of a peptide, in particular a native peptide. Generally, the late-stage peptide modification method includes: (i) maintaining a reaction mixture at a sufficient temperature for a sufficient period of time to form a product. The reaction mixture contains the peptide being modified, which contains one or more tryptophan residues; a sulfynyl reagent; and a solvent. The product formed in step (i) contains a sulfenylated peptide, where the sulfenylation is on at least one of the one or more tryptophan residues of the peptide.
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C40B 50/08 - Synthèse en phase liquide, c.-à-d. dans laquelle tous les blocs servant à créer la bibliothèque sont en phase liquide ou en solution au cours de la création de la bibliothèqueProcédés particuliers de clivage à partir du support liquide
A fusion peptide comprising a coronavirus HR2-derived peptide fused to an ACE2-derived peptide or a lipopeptide comprising the fusion protein and cholesterol is a broad spectrum inhibitor of coronavirus.
A computer-implemented bone-implant system evaluation method for application of mesh-free analysis of a bone-implant system for evaluation of performance of a bone-implant system for an implant implanted within the bone structure at an anatomical site, said method comprising (i) receiving a set of bone structure data set, wherein set of bone structure data includes data indicative of the bone structure at an anatomical site; (ii) inputting an implant data set and inputting the position of the implant data set, wherein the implant is selected based upon the biomechanical requirements for the anatomical site and the position and of the implant data set is indicative of the position of the implant with respect to the anatomical site, wherein implant data set includes data representative of the geometry and materials properties of the implant; (iii) creating a bone-implant model, wherein said bone implant-model includes a mesh-free model of trabecular bone at the anatomical site wherein the bone-implant model is formed from the bone structure data set from step (i) and the implant data set from step (ii), and wherein the mesh-free model of trabecular bone is indicative of the trabecular bone structure of the bone structure at the anatomical site; and (iv) determining a biomechanical result based upon computer simulated loading of the bone-implant system based upon mesh-free analysis of the bone-implant model, wherein the biomechanical result includes data based on the displacement of the implant relative to the bone of bone-implant model.
G06F 30/20 - Optimisation, vérification ou simulation de l’objet conçu
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
12.
Dinuclear platinum (II) red emitters for OLED applications
−1. The Pt(II) complexes disclosed herein can be included in organic light-emitting devices, such as organic light-emitting diodes (“OLEDs”), for use in commercial applications. OLEDs containing these red-emitting Pt(II) complexes can have current efficiency and/or external quantum efficiency that are comparable or higher than commercially available red emitters and prolonged operational lifetime, such as a LT95 at 1000 nits>9000 h for a red OLED.
C07F 15/00 - Composés contenant des éléments des groupes 8, 9, 10 ou 18 du tableau périodique
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
H10K 50/11 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL]
H10K 50/12 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL] comprenant des dopants
H10K 71/12 - Dépôt d'une matière active organique en utilisant un dépôt liquide, p. ex. revêtement par centrifugation
H10K 71/13 - Dépôt d'une matière active organique en utilisant un dépôt liquide, p. ex. revêtement par centrifugation en utilisant des techniques d'impression, p. ex. l’impression par jet d'encre ou la sérigraphie
H10K 71/16 - Dépôt d'une matière active organique en utilisant un dépôt physique en phase vapeur [PVD], p. ex. un dépôt sous vide ou une pulvérisation cathodique
SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION, DBA SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventeur(s)
Hui, Shu Yuen Ron
Tan, Siew Chong
Mi, Chunting Chris
Abrégé
Disclosed is a system for stabilizing a power distribution network. The network is supplied at least partially by a renewable energy source. The system comprises a bidirectional AC-DC power conversion system between a supply 5 side distribution network and a load side grid. for converting a supply side AC voltage, at a supply side frequency. to a load side DC voltage; a voltage regulator for regulating the load side DC voltage; and a supply side control loop comprising at least one of a frequency control loop and a voltage control loop for making a measurement of a respective one of the supply side frequency and 10 supply side AC voltage. and controlling bidirectional power transmission between the bidirectional AC-DC power conversion system and one or more DC loads connected to the load side grid. based on the measurement from the respective frequency control loop and/or voltage control loop.
H02J 3/32 - Dispositions pour l'équilibrage de charge dans un réseau par emmagasinage d'énergie utilisant des batteries avec moyens de conversion
H02J 3/16 - Circuits pour réseaux principaux ou de distribution, à courant alternatif pour règler la tension dans des réseaux à courant alternatif par changement d'une caractéristique de la charge du réseau par réglage de puissance réactive
H02J 3/38 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs
H02M 7/797 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continuTransformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif avec possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
14.
A MICROFLUIDIC PIPELINE FOR ISOLATION AND ANALYSIS OF SINGLE VIRUSES
Advanced Biomedical Instrumentation Centre Limited (Chine)
Centre for Immunology & Infection Limited (Chine)
Inventeur(s)
Shum, Ho Cheung
Poon, Lit Man
Nan, Lang
Lai, Man Yuk Alison
Abrégé
The subject invention pertains to a microfluidic pipeline which enables isolation and analysis of single viruses. Single viruses are encapsulated and manipulated within microfluidic droplets. The subject invention further pertains to the amplification of single viral genomes are amplified and confined within the droplets, followed by extraction and isolation of the single-droplet contents for sequencing analysis.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
Disclosed are methods and compositions for use in preparing dynamic biological macromolecules for high-resolution cryo-electron microscopy or cryo-electron tomography imaging. The compositions contain a metallo-supramolecular branched polymer with a positive zeta potential, containing a hydrophilic polymer segment, a chelating chemical group, and a metal ion. The hydrophilic polymer segment is covalently bonded to the chelating chemical group that is in turn bonded to the metal ion via a dative bond. The methods and compositions can be used to improve particle distribution in vitreous ice and/or to change particle orientations in vitreous ice. Accordingly, the methods and compositions can be utilized to improve particle distribution for high resolution structure determination using single-particle cryo-EM.
G01N 1/42 - Traitement à basse température des échantillons, p. ex. cryofixation
G01N 23/225 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques
16.
METHODS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION SKELETAL SEQUELAE
Methods for treating or preventing a skeletal sequelae of a coronavirus infection in a subject in need thereof, the method comprising administering a therapeutically effective amount of an endothelin receptor antagonist to the subject, with the proviso that the endothelin receptor antagonist is not co-administered with dapagliflozin or niclosamide. The skeletal sequelae can include one or more of arthralgia, viral arthritis, osteopenia, osteochondral damage, and osteoporosis.
A method and systems for making predictions based on a classifierare provided. The method includes receiving a multivariate input having feature variables; making prediction based on a comonotone-independence Bayes classifier (CIBer) via performing conditional probability mass function on the feature variables; and outputting a predictive class. The making prediction based on the comonotone-independence Bayes classifier (CIBer) includes a joint encoding to artificially insert ordering in categorical features. The joint encoding is configured to preserve inherent dependence among the categorical features.
G06F 18/2415 - Techniques de classification relatives au modèle de classification, p. ex. approches paramétriques ou non paramétriques basées sur des modèles paramétriques ou probabilistes, p. ex. basées sur un rapport de vraisemblance ou un taux de faux positifs par rapport à un taux de faux négatifs
18.
BUILDING BLOCKS FOR DIFFICULT PEPTIDE SYNTHESIS AND METHOD OF MAKING THEREOF
Building block structures containing N, O/S-benzylidene acetal dipeptide (NBD) are described. The unique core structure of NBD can effectively convert those difficult peptide/proteins sequence into the easy ones, allowing smooth synthesis of those challenging targets. Further, the production of NBDs is highly robust, and it can be scale up facilely, which can facilitate the research and development of tailor-made peptides/proteins in the future.
A holographic near-eye display device capable of multi-angle simultaneous illumination, comprising a light source module, a spatial light modulator (130), a beam splitter (120), an eyepiece, and a master controller (150). The light source module is used for emitting parallel light of different angles to simultaneously illuminate and cover an effective working region of the spatial light modulator (130). The spatial light modulator (130) is loaded with a hologram and used for modulating incident parallel light of different angles to form diffracted parallel light of different angles, i.e., virtual images of different viewing angles. The parallel light of different angles illuminates the spatial light modulator (130) and is modulated and diffracted via a computer-generated hologram on the spatial light modulator (130), and diffracted image light is converged by a second lens (140) to form different viewpoints for viewing by human eyes. The multi-angle simultaneous illumination does not require additional time-sharing control of an illumination unit, and when the size and position of human eye pupils change, a clear virtual image can always be seen, thereby achieving the objective of expanding an eyebox.
A method of treating a coronavirus infection in a subject in need thereof, the method including administering a therapeutically effective amount of an endothelin receptor antagonist to the subject, with the proviso that the endothelin receptor antagonist is not co-administered with dapagliflozin or niclosamide.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61K 31/422 - Oxazoles non condensés et contenant d'autres hétérocycles
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
21.
A STEERABLE ARM FOR USE IN ENDOSCOPIC SURGICAL PROCEDURES
A steerable arm for use in endoscopic surgical procedures. The steerable arm cut from a tube of nitinol to provide flexibility and resilience by the structure into which the tube is cut. Typically, the cut tube comprises a spiralling coil, the loops of which are in contact on one lateral side of the tube and the tube is bent to open apart the loops on the other lateral side. The material which the tube is made of is capable of retaining memory of the bend. This provides a bias for restoring the tube to the bend whenever a force causing the tube to flex is removed.
A61B 1/018 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments caractérisés par les conduits internes ou par leurs accessoires destinés à recevoir des instruments
A61B 34/00 - Chirurgie assistée par ordinateurManipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
The subject invention pertains to a new class of compounds, N-acryloylindole (NAIs), and methods of using NAIs as cysteine-reactive probes for proteome-wide cysteine profiling and imaging of thiol oxidative modifications. NAIs are capable of imaging oxidized thiols in cells facing oxidative stress by confocal fluorescence microscopy. NAIs can capture populations of cysteines, particularly those involved in gene expression and regulation.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07D 209/08 - IndolesIndoles hydrogénés avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone de l'hétérocycle
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
23.
DIAMOND PARTICLE-BASED PHYSICAL UNCLONABLE FUNCTION MATERIAL, AND PREPARATION METHOD THEREFOR AND USE THEREOF
DONGGUAN INSTITUTE OF OPTO-ELECTRONICS, PEKING UNIVERSITY (Chine)
Inventeur(s)
Chu, Zhiqin
Zhang, Tongtong
Wang, Qi
Wang, Zhongqiang
Abrégé
The present invention provides a diamond particle-based physical unclonable function material, and a preparation method therefor and a use thereof. The material comprises a monocrystalline silicon substrate, and diamond particles having silicon vacancy color centers and grown in situ on the monocrystalline silicon substrate. Preparation of the diamond particles on the silicon substrate relates to a random process, which is a key requirement for manufacturing a physical unclonable function label. According to the present invention, the scattering spectra, morphology features and spatial position relationship of the diamond particles are used as fingerprint information of the diamond physical unclonable function material. Due to extreme heat resistance, mechanical, chemical and light stabilities of a diamond material, the high-robustness label in the present invention can meet the requirements of many practical uses in various environments, and has practical commercial value in huge anti-counterfeit markets such as electronic components, medical packages, vehicles, and luxury goods.
CENTRE FOR VIROLOGY , VACCINOLOGY AND THERAPEUTICS LIMITED (Chine)
Inventeur(s)
Zhou, Jie
Chiu, Man Chun
Li, Cun
Yuen, Kwok Yung
Abrégé
Provided is a robust nasal organoid culture system and fully characterized 2D and 3D in-vitro generated organoids, and methods of using the organoids. The nasal organoids contain a population of differentiated nasal epithelial cells having cellular heterogeneity and molecular markers similar to mature nasal epithelial tissue. Improved methods for generating two-dimensional and three-dimensional nasal organoids are also provided. The methods generally require a two-phase culture system, i.e., expansion and differentiation culture. The provided nasal organoids are suitable for recapitulating nasal tissue complexity for modeling respiratory diseases, studying barrier function and drug delivery, high-throughput drug screening, and assessing the effects of pathogens and environmental toxins on the nasal respiratory epithelium.
A rechargeable aqueous Mg battery is composed of a Mg metal anode, a solid-state aqueous polymer-based electrolyte, and an intercalation-type Prussian blue analogue cathode for ion storage. During battery operation, the Mg anode undergoes dissolution and deposition, while Mg ions in the electrolyte inserts and extracts from the cathode lattice, thereby releasing energy during discharge and storing energy during charge.
The subject invention pertains to a new method for measuring the elastic properties of microfibers by rope-coiling. Rope-coiling refers to the buckling of a slender elastic fiber caused by axial compression. A continuous flow microfluidic method enables the high-throughput measurement of the elasticity of microfibers by rope-coiling, where sample loading and unloading are not needed between consecutive measurements. In certain embodiments the coiling radius can be directly proportional to the elastic modulus of the fiber, facilitating calibration to measure fiber elasticity for high-throughput applications. Throughput can be thousands of times higher than that of a tensile tester, making possible an in situ, on-line measurement in a microfluidic production line, which couples the making of microfibers and the measurement of elasticity on the same line. The new method can also measure certain fibers with local variations in elasticity.
G01N 3/06 - Adaptations particulières des moyens d'indication ou d'enregistrement
G01N 3/08 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique par application d'efforts permanents de traction ou de compression
27.
ZEBRAFISH MODEL OF HUMAN ACUTE MYELOID LEUKEMIA AND METHOD OF USE THEREOF
Genetically modified zebrafish, in which mutation combinations frequently identified in human AML are stably expressed in the stem cell population of the fish, are provided. The combination of mutations result in morphologic, cytochemical and molecular changes of its blood cells that are remarkably similar to those in human AML. The zebrafish model provides a foundation for the study of AML initiation and progression and a high throughput in vivo drug screening platform to identify personalized therapies for AML based on specific mutation combinations. The method of drug screening includes contacting embryos or adult fish containing mutations as disclosed herein, with a test agent, at test concentrations and test intervals to determine the therapeutic effect if any, of the test agent.
The invention relates to the field of biomedicine. In particular, the invention relates to a live strain of Staphylococcus aureus and uses thereof. More particularly, the invention relates to a live strain of Staphylococcus aureus which lacks adenosine synthase A (AdsA) activity, to a vaccine against Staphylococcus aureus infection comprising said live strain, and a method for preventing and/or treating Staphylococcus aureus infection in a subject by administering said live strain.
The subject invention pertains to a system for the electrochemical conversion of nitrate to ammonia. The electrolysis is carried out using a cell with a working electrode having a CuDATA molecular catalyst absorbed on carbon black. The system is effective for the conversion of waste nitrate solutions to ammonia. The conversion occurs with a high faraday efficiency of about 98%.
C25B 11/091 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’au moins un élément catalytique et d’au moins un composé catalytiqueÉlectrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques
Advanced Biomedical Instrumentation Centre Limited (Chine)
Inventeur(s)
Chow, Shing Fung
Low, Kam Hung
Wong, Si Nga
Abrégé
The subject invention pertains to cocrystals of dexamethasone (DEX) and a benzenediol cocrystal composed of a 1:1 molar ratio of DEX and the benzenediol. The benzenediol can be catechol (CAT) or resorcinol (RES). The DEX and benzenediol cocrystal are formed by grinding crystalline DEX where the crystalline benzenediol are combined in the 1:1 molar ratio. Grinding can be performed at room temperature. Cocrystals can be thermally annealed or exposed to humidity to enhance cocrystal formation. The DEX−CAT or DEX-RES cocrystals can be included in a medicament for use in treatments for allergies, asthma, rhinitis, cancer, diabetes, anemia, ulcers, and viral infections. The DEX−benzenediol cocrystal can be sieved to provide particles that are in the range of 10 to 45 μm that can be used for intranasal administration with improved dissolution performance.
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
C07C 37/84 - SéparationPurificationStabilisationEmploi d'additifs par traitement physique par cristallisation
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The subject invention pertains to a Cas9 protein with an amino acid mutation at residues 888, 889, or a combination thereof of a WED domain and/or residues 988, 989, or a combination thereof of a PI domain. The subject invention can further pertain to a Cas9 protein with mutations at amino acid positions N986, D987, L988, L989, or any combination thereof. The subject invention also pertains to a method of enhancing the activity of KKH-SaCas9. In addition, a method of machine learning-based in silico screens for genome editing protein engineering is provided, including steps of populating a predictive machine learning model with an input dataset comprising empirical measurements of on-target activities of sgRNAs paired with a screening library of genome editing enzyme variants; running the predictive machine learning model with predefined parameters; and evaluating performance of the predictive machine learning model.
Disclosed is a method of obtaining preparing an extract of Spatholobus suberectus Dunn, which contains total flavonoid and proanthocyanidins. The disclosure relates to a method for extracting an active fraction from Spatholobus suberectus. Also provided is the SSP, the active fraction, and a composition thereof. Further provided is a method of treating viral diseases such as COVID-19 disease caused by SARS-CoV-2, and use of the SSP and the active fraction in the manufacture of preparations for prevention and/or treatment of a viral disease.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
LABORATORY FOR SYNTHETIC CHEMISTRY AND CHEMICAL BIOLOGY LIMITED (Chine)
Inventeur(s)
Che, Chi Ming
Fu, Zhiwen
Leung, Yiu Chung Gulice
Abrégé
Synthetic agrimol B and derivatives thereof ( "compounds" ) that have anticancer properties are disclosed. Methods for synthesizing the compounds with an overall yield ≥ 7% are disclosed. Pharmaceutical formulations in forms suitable for the delivery of the compounds to a subject in need thereof are disclosed. Methods of using the compounds for treating a cancer, reducing a cancer, or treating or ameliorating one or more symptoms associated with a cancer, such as non-small-cell lung cancer, in a subject are also disclosed. The methods include (i) administering to the subject the pharmaceutical formulation containing one or more compounds, for one or more times. The compounds can selectively kill cancer cells and/or cancer stem cells over non-cancerous cells by inducing mitochondria dysfunction and/or inhibiting ER to Golgi trafficking in the cancer cells and/or cancer stem cells.
C07C 49/84 - Cétones comportant un groupe cétone lié à un cycle aromatique à six chaînons contenant des groupes éther, des groupes , des groupes ou des groupes
C07C 49/83 - Cétones comportant un groupe cétone lié à un cycle aromatique à six chaînons contenant des groupes hydroxyle polycycliques
C07C 45/45 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par condensation
C07C 45/61 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par des réactions ne créant pas de groupe C=O
Disclosed in the present invention are benzothiazole compounds as well as a preparation method therefor and the use thereof. The compounds have a great inhibition effect on SARS-CoV-2 and can be used for resisting the novel coronavirus. (I)
C07D 277/66 - Benzothiazoles avec uniquement des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués liés en position 2 avec des cycles ou des systèmes cycliques aromatiques liés directement en position 2
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61P 31/14 - Antiviraux pour le traitement des virus ARN
35.
Targeting papain-like protease for broad-spectrum coronaviruses inhibition
Centre for Virology, Vaccinology and Therapeutics Limited (Chine)
Inventeur(s)
Yuan, Shuofeng
Chan, Fuk Woo Jasper
Yuen, Kwok Yung
Abrégé
The subject invention pertains to compounds and methods of using said compounds to target the multi-functional papain-like protease (PLpro) domain of the viral Nsp3, specifically F0213, F0326, and F0393 that can have broad anti-coronavirus activity, including SARS-CoV-2, MERS-CoV, and coronaviruses hCoV-229E and hCoV-OC43. F0213, F0326, and F0393 can possess a dual therapeutic functionality that suppress CoV replication via blocking viral polyprotein cleavage, as well as promote antiviral immunity by antagonizing the PLpro deubiquitinase activity.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes
36.
RATIONALLY DESIGNED SINGLE-ROUND INFECTIOUS VIRUS AND METHODS OF USE THEREOF
CENTRE FOR VIROLOGY , VACCINOLOGY AND THERAPEUTICS LIMITED (Chine)
Inventeur(s)
Kok, Kin Hang
Yuen, Chun Kit
Yuen, Kwok Yung
Wong, Wan Man
Abrégé
Provided are engineered, replication-deficient influenza viruses that are infectious and stimulate broadly-cross protective immunity against multiple different influenza strains. Also provided are compositions and methods for providing protective immune responses against influenza. The methods deliver compositions of intact, replication-deficient influenza viruses by intradermal administration in an amount effective to elicit or stimulate a cross-protective immune response to influenza viruses in the recipient following a single administration. Because the engineered influenza viruses are non-replicating, they are safe and effective in immunocompromised subjects. Also provided are methods for delivering co-stimulatory molecules, growth factors, adjuvants and/ or cytokines together with the non-replicating influenza viruses.
Laboratory for Synthetic Chemistry and Chemical Biology Limited (Chine)
Inventeur(s)
Che, Chi Ming
Wang, Tingting
Wang, Haixu
Abrégé
Methods for asymmetric cis-dihydroxylation (“AD”) of quinones to produce cis-diols of quinones with high yield (i.e. a yield ≥30%) and high enantioselectivity (i.e. an enantiometric excess ≥30%) are disclosed. The method uses an iron-based catalyst, such as one or more Fe(II) complexes, as the catalyst, and can be performed under mild reaction conditions (e.g. a temperature ≤50° C. at 1 atom in open air). The method generally includes: (i) maintaining a reaction mixture at a temperature for a period of time sufficient to form a product, where the reaction mixture contains a quinone, one or more iron-based catalyst(s), and a solvent, and where the product contains a chiral cis-diol. Optionally, the method also includes adding an oxidant into the reaction mixture prior to and/or during step (i), such as a hydrogen peroxide solution.
C07C 50/30 - Quinones contenant des groupes dont les atomes d'oxygène sont liés par liaison simple à des atomes de carbone à structure quinoïde polycyclique non condensée
C07C 50/34 - Quinones contenant des groupes dont les atomes d'oxygène sont liés par liaison simple à des atomes de carbone la structure quinoïde faisant partie d'un système cyclique condensé à trois cycles
C07C 50/36 - Quinones contenant des groupes dont les atomes d'oxygène sont liés par liaison simple à des atomes de carbone la structure quinoïde faisant partie d'un système cyclique condensé d'au moins quatre cycles
38.
IRON-CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES
LABORATORY FOR SYNTHETIC CHEMISTRY AND CHEMICAL BIOLOGY LIMITED (Chine)
Inventeur(s)
Che, Chi Ming
Wang, Tianting
Wang, Haixu
Abrégé
ciscisciscis-diol. Optionally, the method also includes adding an oxidant into the reaction mixture prior to and/or during step (i), such as a hydrogen peroxide solution.
C07C 29/48 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par des réactions d'oxydation avec formation de groupes hydroxyle
C07C 35/14 - Composés comportant au moins un groupe hydroxyle ou O-métal lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons monocycliques contenant des cycles à six chaînons avec plusieurs groupes hydroxyle liés au cycle
B01J 31/28 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant en outre des composés métalliques inorganiques non prévus dans les groupes du groupe du platine, du cuivre ou du groupe du fer
39.
NEUTRALIZING ANTIBODIES AGAINST COVID-19 AND METHODS OF USE THEREOF
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (Chine)
Inventeur(s)
Chen, Zhiwei
Zhou, Runhong
Zhou, Biao
Luo, Mengxiao
Chen, Bohao
Abrégé
Disclosed are compositions and methods using antibodies and antibody fragments that bind SARS-CoV-2 spike protein or receptor binding domain (RBD). Generally, the CDRs of the antibodies and antigen binding fragments comprise: (a) the three light chain CDRs selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, and 64; and (b) the three light chain CDRs selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, and 63.In some forms, the antibody is a bispecific antibody.
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (Chine)
Inventeur(s)
Zhao, Hanjun
Yuen, Kwok-Yung
Abrégé
Antiviral peptides and formulations thereof are described for use in treating or preventing one or more symptoms of coronavirus infections. Peptides derived from human beta defensin 2 have been shown to have antiviral properties against different variants of coronavirus including cross-linking viral particles, blocking cell-to-cell fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via intranasal route to prevent or alleviate one or more symptoms of coronavirus infections such as reducing the syncytial formation and lung damage.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
Provided are a composition comprising a peptide conjugated to a TLR agonist, including TLR7 agonist 1v209, and methods of using the composition. The methods comprise administering the peptide-based vaccine conjugate to a subject. The peptide-based vaccine conjugate inhibits tumor growth and induces antigen-specific B and T cell responses in a subject.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
Disclosed is a compact, lightweight hydraulic manipulation system used for underwater applications consisting of two parts: a modulus hybrid underwater manipulator and a compact lightweight hydraulic control framework. The system is used for general underwater work such as underwater sampling, hyperbaric welding, and marine aquaculture.
Described herein are two-coordinated d10 metal carbene complexes containing (i) Cu (I), Ag (I), or Au (I), (ii) a pyrazine-fused NHC ligand or a pyridine-fused NHC ligand, and (iii) a carbazole ligand, a pyrido [2, 3-b] indole ligand, or a pyrido [3, 4-b] indole ligand. The radiative properties of the compounds can be controlled by thermally activated delayed fluorescence. The emission colors of the complexes can be tuned by using carbazoles with varying donor strength. Also described are methods of using the complexes.
Provided are two fully humanized Δ42PD1-specific mAbs, specifically huCH101 and huCH34 at 97.0% humanness by CDR grafting. Provided is a method of using huCH101 and/or huCH34 to treat subjects in need of Δ42PD1-specific mAb, including subjects with cancer and/or infection.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
The present invention provides an antibacterial and antiviral copper-containing stainless steel, and a preparation method for and the use of a stainless steel conforming to the composition thereof. The copper-containing stainless steel comprises a stainless steel matrix and a copper-rich phase evenly distributed in the stainless steel matrix, wherein the copper content of the copper-containing stainless steel is 6-30 wt%. The preparation method therefor comprises the manufacturing of a small stainless steel product mainly using powder metallurgy technology, and the manufacturing of a large stainless steel sheet, bar or pipe mainly using a composite process without significant thermal deformation. Compared with a traditional antibacterial stainless steel, the composition design of the present invention contains sufficient copper-rich precipitated phases, such that the antibacterial and antiviral copper-containing stainless steel of the present invention can achieve both a good killing effect on bacteria and a virus killing capacity comparable with that of pure copper, can be used for preparing the integral body or the whole of parts such as cutters, elevator buttons, railings, handrails, door handles and cups, and can effectively kill bacteria and viruses existing on the surfaces thereof.
The present invention relates to a compound for treating fungal disease, wherein said compound provide target-specific inhibition of fungal adhesion, biofilm formation, and filamentation without affecting their growth, at very low concentration. The compound of the present invention is selected from FDA approved drugs Cangrelor. Further, the present invention provides a composition comprising compound of the present invention and a pharmaceutically acceptable carrier. Further, the present invention provides a method of treating fungal infections using the compound and/or composition of the present invention. Furthermore, uses of the compound and/or composition is also being provided in the present disclosure.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
LABORATORY FOR SYNTHETIC CHEMISTRY AND CHEMICAL BIOLOGY LIMITED (Chine)
Inventeur(s)
Che, Chi-Ming
You, Tingjie
Abrégé
Described herein is an iron(II)-phthalocyanine catalyzed C—H bond amination of alkyl azides. The catalyst is effective to produce intramolecular amination of saturated C—H bonds in moderate to excellent yields and the methods are tolerant of a wide scope of substrates. The methods described are useful for the synthesis of natural products derivatives and for the late-stage functionalization of pharmaceuticals.
C07D 207/06 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux contenant uniquement des atomes d'hydrogène et de carbone, liés aux atomes de carbone du cycle
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
49.
AEROSOLIZED VITAMIN A FOR MANAGEMENT OF COVID–19-RELATED OLFACTORY DYSFUNCTION
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (Chine)
HALCYON LIFE SCIENCES TECHNOLOGY LIMITED (Chine)
Inventeur(s)
Chung, Wai Hin
Hung, Ivan Fan Ngai
Sze, Kong Hung
Sridhar, Siddharth
Yan, Bingpeng
Yuen, Kwok Yung
Abrégé
Disclosed are compositions and methods useful for management of rhinological, neurological, or psychiatric complaints and disorders. The rhinological, neurological, or psychiatric complaint and disorder can be one that affects the normal human neurosensory, neurocognitive, or neuropsychiatric functions, including but not limited to olfactory dysfunction. The complaint or disorder can be one that is related to coronavirus disease 2019 (COVID-19), including but not limited to olfactory dysfunction. Disclosed are compositions including a vitamin A solution and an essential oil mixture. The vitamin A solution can be a vitamin A compound and a nontoxic solvent, such as a pharmaceutically acceptable solvent. The vitamin A compound can be at a concentration of from 10,000 to 120,000 international units (IU). The vitamin A solution and the essential oil mixture can be in a ratio of from 4: 1 to 1: 4 in the composition. The composition of vitamin A solution and essential oil mixture can be aerosolized and administered via the subject's nose.
The subject invention pertains to methods and compositions for treating hypertension. In specific embodiments, the methods comprise administering KSD179019 to a subject in need of hypertension treatment. In further embodiments, the methods comprise administering a KSD179019 analog or derivative to a subject in need of hypertension treatment. Also provided are methods to design and manufacture KSD179019 analogs and derivatives with enhanced and prolonged anti-hypertensive therapeutic efficacy.
Embodiments of the present invention provide a video timing motion nomination generation system and a method, which process, by means of an encoder, video features that are extracted from an inputted video so as to obtain video encoding features having global information, and extract corresponding segment features of interest from the video encoding features by means of a plurality of pre-trained nomination segments to provide to a decoder; the decoder generates segment features on the basis of the segment feature of interest corresponding to each nomination segment and a nomination feature corresponding to each pre-trained nomination segment, and provides same to a prediction module; and the prediction module generates a timing motion nomination result on the basis of the segment features from the decoder. The solution of the embodiments of the present invention can effectively capture global context information of a video and obtain video encoding features that have a stronger representation ability. Moreover, by introducing several learnable nomination segments to extract feature sequences of corresponding positions from the video encoding features for subsequent prediction, which improves training convergence speed and greatly reduces computational burden.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
52.
AN APPARATUS FOR DETECTING ENTRY AND EXIT BY CROSSING A VIRTUAL LINE
An entry/exit detection apparatus has two separate signal transmitters (T1,T2) with a signal blocking device (SBD) in-between them. Based on this apparatus, a virtual line (16) is established for detecting whether an object or a person (A) crossed the virtual line (16) and entered or exited from a place or vehicle which has the virtual line (16) at its entrance. The place may be a building, market, shop, restaurant, bank, school, lift (elevator), room, or car. When the object or person (A) with the portable device crosses this virtual line, the motion is detected by the detector monitoring signal from the two transmitters. The portable device will be able to detect and recognize it has crossed the virtual line automatically based on the signals received from these two signal transmitters.
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
54.
ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (Chine)
Inventeur(s)
Zhou, Jie
Chiu, Man Chun
Li, Cun
Yuen, Kwok Yong
Abrégé
Methods for obtaining a population of differentiated alveolar cells, differentiated alveolar cells in the form of alveolar organoids generated by the methods and uses for the differentiated alveolar organoids are provided. The methods include digesting long-term expanding lung organoids (LO) into single cells (i.e., dissociated cells), and suspension culturing the dissociated cells in distal differentiation (DD) cell culture media in a non-adherent plate for an effective amount of time. Alveolar organoids includes a population of AT1 and AT2 cells and in suspension culture exhibit an apical-out polarity and include abundant cytoplasmic lamellar bodies and microvilli. The alveolar organoids can be utilized alone or in combination with 2D and 3D AWO, rebuilt the human respiratory epithelium in culture plates for studying biology and pathology of human respiratory system, including, but not limited to, the study of COVID-19 respiratory diseases.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 35/42 - Appareil respiratoire, p. ex. poumons, bronches ou cellules pulmonaires
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
55.
DEVELOPMENT OF SYNTHETIC PSEUDAMINIC ACID-BASED ANTIBACTERIAL VACCINES AGAINST ACINETOBACTER BAUMANNII
Provided are compositions comprising chemically synthesized pseudaminic acid (Pse) conjugated to a carrier protein using the OPA chemistry, methods of using said compositions to stimulate immune responses in subjects and protect the vaccinated subjects from infections caused by Pse-producing A. baumannii.
The present invention provides a video action detection method based on an end-to-end framework, and an electronic device. The end-to-end framework comprises a backbone network, a positioning module, and a classification module. The method comprises: performing, by the backbone network, feature extraction on a video clip to be detected to obtain a video feature map of said video clip, wherein the video feature map comprises feature maps of all frames in said video clip; extracting the feature map of a key frame from the video feature map by the backbone network, obtaining an actor location feature from the feature map of the key frame, and obtaining an action category feature from the video feature map; determining an actor location by the positioning module according to the actor location feature; and determining, by the classification module, the action category corresponding to the actor location according to the action category feature and the actor location. The video action detection method provided by the present invention is relatively low in complexity, and can achieve better detection performance.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
57.
FABRICATION AND APPLICATION OF FIBER-BASED HYDROGEL USING ALL-AQUEOUS FORMULATIONS
Disclosed is a fiber-based hydrogel containing an aqueous hydrogel containing biocompatible microfibers having a high aspect ratio length to diameter suspended in water, the biocompatible microfibers mechanically interlocked. By simply adjusting the fiber aspect ratio, the fiber-based hydrogels can tune a considerable range of mechanical properties and drug release rates for clinical use. The fiber-based hydrogel has favorable biocompatibility and accelerated tissue regeneration ability demonstrated by a mice excision skin model.
A novel medical image generation approach synthesizes thin-cut computerized tomography (CT) images from thick-cut CT ones as inputs. First thick-cut CT images are obtained by maximizing the pixel-wise intensity of five or more than five continuous thin-cut ones after image registration. Second, the obtained thick-cut CT images are fed into a generator block which adopts an encoder-decoder architecture, where each thick-cut image is encoded into low-dimensional embedding space before decoding into multiple thin-cut ones. Third, a discriminator focuses on distinguishing original real thin-cut images from synthetic thin-cut images. An adversarial mechanism between the generator and discriminator causes the discriminator's output to provide an effective gradient update of the network parameters for the generator to increasingly improve the generator's ability to synthesize higher-quality thin-cut images and in turn promotes the discriminator's discriminating capability.
Disclosed is a three dimensional classification system for recognizing cross-sectional images automatically containing a processor that executes: rescaling a plurality of cross-sectional images, and feeding the rescaled plurality of cross-sectional images into two branches; feeding the rescaled plurality of cross-sectional images into a first branch for performing a plurality of convolutions on the rescaled plurality of cross-sectional images directly to learn features for distinguishing phases; feeding the rescaled plurality of cross-sectional images into a second branch for reducing resolution, then performing a plurality of convolutions on the reduced resolution plurality of cross-sectional images to learn features for distinguishing phases; and concatenating convolutional output channels from the two branches to fuse global and local features, on which two fully-connected layers are stacked as a classifier to recognize cross-sectional volumetric images accurately and quickly.
SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION, DBA SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventeur(s)
Hui, Shu Yuen, Ron
Tan, Siew Chong
Mi, Chunting, Chris
Abrégé
Disclosed is a system for stabilizing a power distribution network. The network is supplied at least partially by a renewable energy source. The system comprises a bidirectional AC-DC power conversion system between a supply 5 side distribution network and a load side grid, for converting a supply side AC voltage, at a supply side frequency, to a load side DC voltage; a voltage regulator for regulating the load side DC voltage; and a supply side control loop comprising at least one of a frequency control loop and a voltage control loop for making a measurement of a respective one of the supply side frequency and 10 supply side AC voltage, and controlling bidirectional power transmission between the bidirectional AC-DC power conversion system and one or more DC loads connected to the load side grid, based on the measurement from the respective frequency control loop and/or voltage control loop.
H02J 3/18 - Dispositions pour réglage, élimination ou compensation de puissance réactive dans les réseaux
H02J 3/16 - Circuits pour réseaux principaux ou de distribution, à courant alternatif pour règler la tension dans des réseaux à courant alternatif par changement d'une caractéristique de la charge du réseau par réglage de puissance réactive
B60L 53/50 - Stations de charge caractérisées par des moyens d’emmagasinage ou de production d'énergie
61.
DINUCLEAR PLATINUM EMITTER COMPLEXES AND METHODS OF MAKING AND USING THEREOF
Described herein are dinuclear platinum (II) emitter complexes and their methods of making and using thereof. The design of the dinuclear platinum (II) emitters results in short radiative lifetimes and high quantum yields. The dinuclear platinum (II) emitter complexes can be used to fabricate blue emitting OLEDs.
Described herein are compounds containing palladium (II), as the central metal atom, and tetradentate [N^C^C^N] ligands. The compounds are charge neutral, and feature a donor-acceptor structure where a pendant substituted amino group (such as unsubstituted diphenylamine or substituted diphenylamine) and a heteroaryl group (such as pyridine group) serve as donor and acceptor, respectively. This donor-acceptor structure introduces a set of low-energy singlet and triplet charge-transfer excited states with small energy separation allowing for efficient thermally activated delayed fluorescence to take place.
C07F 15/00 - Composés contenant des éléments des groupes 8, 9, 10 ou 18 du tableau périodique
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
63.
DINUCLEAR PLATINUM (II) RED EMITTERS FOR OLED APPLICATIONS
Platinum (II) complexes ( "Pt (II) complexes" ) that can emit in the red and/or deep red regions and methods of making and using thereof are described. These Pt (II) complexes can have dinuclearity with close Pt-Pt contact and close interplanar distance, allowing for high emission quantum yield, such as > 50%, short emission lifetime, such as < 3 μs, and high radiative decay rate, such as in the order of 10 5s -1. The Pt (II) complexes disclosed herein can be included in organic light-emitting devices, such as organic light-emitting diodes ( "OLEDs" ), for use in commercial applications. OLEDs containing these red-emitting Pt (II) complexes can have current efficiency and/or external quantum efficiency that are comparable or higher than commercially available red emitters and prolonged operational lifetime, such as a LT95 at 1000 nits >9000 h for a red OLED.
C07F 15/00 - Composés contenant des éléments des groupes 8, 9, 10 ou 18 du tableau périodique
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
H01L 51/50 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés pour l'émission de lumière, p.ex. diodes émettrices de lumière organiques (OLED) ou dispositifs émetteurs de lumière à base de polymères (PLED)
64.
DEVICES AND METHODS FOR ORIENTING A SURGICAL DEVICE
Devices and methods are provided that simplify and improve placement of stabilizing orthopedic pins, wires, and/or screws in the pelvis in minimally invasive surgery. Provided is a surgical instrument guide containing an adjustable friction clamp for positioning and securing a cannula, and a probe with a blunt, nonpenetrating tip. The probe and a surgical instrument held by the friction clamp are oriented at right angles to one another. In use, the blunt probe is introduced through a small incision and advanced by blunt dissection until the blunt tip is positioned at a desired anatomical landmark on the surface of the pelvis. A cannula inserted through the friction clamp is advanced until the tip of the cannula is within 2 cm of the blunt tip of the probe; an orthopedic pin, wire, and/or screw can then be inserted through the cannula to provide stabilization. The blunt probe may be cannulated.
Provided are an Eye Movement analysis with Hidden Markov Model (EMHMM) with co-clustering, an Eye Movement analysis with Switching Hidden Markov Models (EMSHMM) to analyze eye movement data in cognitive tasks involving stimuli with different feature layouts and cognitive state changes, a switching hidden Markov model (SHMM) to capture a participant's cognitive CN state transitions during the task and an EMSHMM to assess preference decision-making tasks with two or more cognitive states. The EMSHMM provides quantitative measures of individual differences in cognitive behavior/style, making a significant impact on the use of eye tracking to study cognitive behavior across disciplines.
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
66.
SURGERY DEVICE WITH PATIENT-SPECIFIC FIBULA MALLEOLUS CAP
Described are fibula malleolus caps and surgery devices with fibula malleolus caps. The fibula malleolus caps may be patient-specific fibula malleolus caps. The devices with patient-specific fibula malleolus caps overcome the sliding and rotational errors during fibula flap harvesting. A comparative clinical study demonstrates that the fibula malleolus cap enhances the accuracy of fibula flap harvesting, leading to accurate location and angulation of simultaneous dental implants.
An electromechanical sensor and a method of sensing an object or a tactile input using the sensor. The sensor includes: a base provided with a magnetic sensor arranged to detect a change in magnetic flux at the position of the magnetic sensor; a flexible film adjacent to the magnetic sensor; and a magnetic element provided on the flexible film; wherein the magnetic element is arranged to move relative to the magnetic sensor when the flexible film is reversibly deformed by an external force applied to the flexible film.
G01R 33/06 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs galvano-magnétiques
G01B 7/14 - Dispositions pour la mesure caractérisées par l'utilisation de techniques électriques ou magnétiques pour mesurer la distance ou la marge entre des objets ou des ouvertures espacés
G01B 7/24 - Dispositions pour la mesure caractérisées par l'utilisation de techniques électriques ou magnétiques pour mesurer les déformations dans un solide, p. ex. au moyen d'une jauge de contrainte à résistance en utilisant la variation des propriétés magnétiques
G01L 1/12 - Mesure des forces ou des contraintes, en général en mesurant les variations des propriétés magnétiques d'un matériau, résultant de l'application d'un effort
G01V 3/08 - Prospection ou détection électrique ou magnétiqueMesure des caractéristiques du champ magnétique de la terre, p. ex. de la déclinaison ou de la déviation fonctionnant au moyen de champs magnétiques ou électriques produits ou modifiés par les objets ou les structures géologiques, ou par les dispositifs de détection
G01R 33/07 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs galvano-magnétiques des dispositifs à effet Hall
G01D 5/14 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens électriques ou magnétiques influençant la valeur d'un courant ou d'une tension
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (Chine)
Inventeur(s)
Zhao, Hanjun
Yuen, Kwok-Yung
Abrégé
Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting in viral resistance. Preferably, the antiviral compositions contain P16 or a P16-like peptide which can both inhibit viral fusion and endosomal acidification to prevent viral entry through the endocytic pathway. The antiviral compositions can be used in methods of treating diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A (H1N1) pdm09 virus, avian influenza A (H7N9) virus, and the non-enveloped rhinovirus. The compositions are administered in a subject in need thereof in an effective amount to reduce or prevent viral replication in the subject, and thus reduce one or more symptoms of disease, disorder, or illness associated with virus.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A steerable arm (301) for use in endoscopic surgical procedures. The steerable arm (301) cut from a tube of nitinol to provide flexibility and resilience by the structure into which the tube is cut. Typically, the cut tube comprises a spiralling coil (707), the loops of which are in contact on one lateral side of the tube and the tube is bent to open apart the loops on the other lateral side. The material which the tube is made of is capable of retaining memory of the bend. This provides a bias for restoring the tube to the bend whenever a force causing the tube to flex is removed.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
G02B 23/24 - Instruments pour regarder l'intérieur de corps creux, p. ex. endoscopes à fibres
70.
Method for peritoneal metastatic cell detection and isolation thereof
Provided herein is a method for the detection and isolation of metastatic cells from a sample obtained from a subject. Also provided is a device comprising a microchip for use in the method. Also provided is a method of isolating the metastatic cells for culture and characterization. Provided herein is a kit for the method therein.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Live attenuated viruses for protection against the novel coronavirus Sars-CoV-2 are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza A or B virus (LAIVA/B), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-A/B-Sars-CoV-2-CoV2Ag. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33℃. Compositions including the chimeric virus also provided as a co-composition with a LAIVA/B. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. The co-compositions can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2 and influenza A and/or B.
A nanostructured composite membrane filter for rapid water purification and methods for preparing the nanostructured composite membrane filter are provided. The nanostructured composite membrane includes a silver layer having a plurality of silver functionalized nanofibers for disinfecting microorganisms of water, and a chemical modified layer having a plurality of chemical modified nanofibers for removing impurities from the water. The plurality of silver functionalized nanofibers includes a plurality of polyvinyl alcohol (PVA) nanofibers coated with polydopamine (PDA) and silver, and each of the plurality of chemical modified nanofibers includes a polymer matrix such as polyvinyl alcohol (PVA) and anionic polyelectrolytes such as poly (sodium styrenesulfonate) (PSSNa) for capturing metal ions of the water.
A power converter circuit includes: a direct current (DC) side; a first passive network; a first current switching network; at least one floating capacitor; a second current switching network; a second passive network; and an alternating current (AC) side. The first passive network is connected between the DC side and the first current switching network for linking the DC side and the first current switching network. The first current switching network comprises at least four serially linked switches for switching the power converter circuit between switching cycles. The at least one floating capacitor is connected to the first current switching network. The second current switching network comprises two pairs of switches for providing an interface between the first current switching network and the second passive network. The second passive network is connected between the second current switching network and the AC side.
H02M 7/797 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continuTransformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif avec possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
74.
Amyloid precursor protein as a diagnostic marker for biliary atresia
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
75.
LIVE ATTENUATED SARS-COV-2 VIRUS IMMUNOGENIC COMPOSITIONS, METHODS OF MAKING AND USING
Provided are a live attenuated SAR-CoV-2 virus (Ca-DelMut-LASV), compositions comprising the live attenuated virus and methods for increasing an immune response to Sars-CoV-2. Ca-DelMut-LASV is characterized by a deletion of the amino acid sequence NSPRRARSVA (SEQ ID NO: 1), which represents a deletion of amino acids 665-705 of the wild type SARS-CoV-2 spike. Ca-DelMut-LASV additionally includes the following mutations relative to wild type SARS-CoV-2: an A578V mutation in the NSP3 protein; a P25L mutation in the spike protein; a V367F in the spike protein; an F20S in the E protein and a V62L mutation in ORF8.
POSTECH ACADEMY-INDUSTRY FOUNDATION (République de Corée)
VERSITECH LIMITED (Chine)
Inventeur(s)
Kim, Dong Pyo
Kim, Ji Tae
Lee, Hyune Jea
Abrégé
The present invention relates to a method for controlling an ultrafast chemical reaction using a microfluidic reactor, and more specifically, the present invention relates to a method for controlling an ultrafast chemical reaction such as the Fries rearrangement reaction and the like by using a microfluidic reactor by the 3D metal printing technique.
The NS1 protein of influenza virus is a key virulent element with multi-functional roles in virus replication and acts as a strong interferon (IFN) antagonist. A live attenuated virus (LAIV) is provided using a master backbone, which contains the influenza B (HK8038) virus and includes a deletion of the NSI coding region (DelNS1). The LAIV is based on novel adaptive mutations, which support DelNS1 influenza B live attenuated virus (LAIV) replication in vaccine producing cells. DelNS1 influenza B LAIV shows spontaneous cold adaption with preference to grow at 30-33° C. but restriction at 37-39° C. The LAIV can be used to protect a subject, against a lethal challenge of antigenic distant influenza B viruses. DelNS1 LAIV with adaptive mutations for growing in vaccine producing systems is an important strategy for making highly attenuated and immunogenic live attenuated influenza vaccines with the ability to induce broad cross protective immunity for seasonal influenza.
Provided herein are novel ortho-Phthalaldehyde (OPA) containing linkers (OPA-L) and the use of OPA-L for the preparation of Antibody-drug conjugate (ADC) via the formation of Phthalimidine through the reaction of primary amine on antibody (e.g., residue of Lysine) and ortho-Phthalaldehyde. The advantage of this OPA-L is high reactivity and can be applied in different types of antibodies to form stably-linked conjugates. The use of OPA-L for the preparation of ADC is advantageous for mild and wide condition of conjugation, for instance, low percentage of organic solvent required, wide range of pH and temperature can be used.
C07D 207/452 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant deux atomes d'oxygène liés directement en positions 2 et 5 par une double liaison avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux autres atomes de carbone du cycle, p. ex. maléimide avec des radicaux hydrocarbonés, substitués par des hétéro-atomes, liés directement à l'atome d'azote du cycle
C07C 235/78 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné avec des atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques d'un squelette carboné non saturé le squelette carboné contenant des cycles
C07D 241/04 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07C 233/61 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons doubles
C07K 1/113 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs sans changement de la structure primaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
79.
APPARATUS AND METHOD FOR MULTIPLEXED ROTATING IMAGING BIOASSAYS
Systems and method for versatile multiplexed spinning/rotating bioassays are provided. This bioassay platform can take the advantage of the high-speed spinning motion, which naturally provides on-the-fly cellular imaging at the rate that cannot be reached by the conventional cameras or laser-scanning techniques, but ultrafast imaging modalities. More importantly, the functionalized solid substrates derived from the disk substrate can be compatible with adherent cell culture as well as biochemically-specific cell-capture, which can now be assayed with ultrafast imaging modalities at an ultra-high-speed line-scan rate of >10 MHz. Large-format spinning high-throughput imaging assay could thus be a potent tool for scaling both the assay throughput as well as content/multiplexity as demanded in many applications, e.g. drug discovery, and rare cancer cell screening.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
80.
A LIVE STRAIN OF STAPHYLOCOCCUS AUREUS AND USES THEREOF
Devices that convert heat into electricity, and methods for a fabrication of the same are provided. The asymmetric thermo-electrochemical capacitor uses a GO-based positive electrode and a battery-type negative electrode to open up the operating voltage window and enhance the electrical discharge capacity for converting low-grade heat into electricity with excellent efficiency, fast thermo-charging time, and stable cycles. The thermo-electrochemical device includes a carbon-based positive electrode, a conductive polymer or a metal-organic framework as negative electrode, a current collector, and a porous separator.
A computer implemented method for searching electronic documents, and associated system and computer program product. The method includes receiving an input representing an example-based search query and processing the input. The method also includes determining, for each of the electronic documents, a relevance score between the input and the corresponding electronic document. The determination is based on, at least, textual similarity between the input and the corresponding electronic document, topical similarity between the input and the corresponding electronic document, as well as linkage relationship in a linkage network of the plurality of electronic documents. The method also includes determining, based on the determined relevance scores, a search result containing one or more of the electronic documents. The search results will be provided to the user.
G06F 16/9038 - Présentation des résultats des requêtes
G06F 16/30 - Recherche d’informationsStructures de bases de données à cet effetStructures de systèmes de fichiers à cet effet de données textuelles non structurées
83.
COMPOSITIONS AND METHODS FOR BROAD SPECTRUM ANTI-VIRAL THERAPY
Provided herein is formulations, systems and methods in which one or more compounds that inhibit AP2M1interaction with a protein motif utilized for trafficking of a viral protein are used to treat a broad range of viral infections. An example of such a compound is N- (p-amylcinnamoyl) anthranilic acid (ACA). Viral infections that are suited to such an approach include those caused by RNA viruses in which virally encoded proteins utilized for transport of viral RNA into the cell nucleus include a YxxØ motif, wherein Ø represents an amino acid with a bulky hydrophobic side chain and x can be any amino acid. Examples of suitable viruses include various strains of influenza virus and coronavirus (e.g. SARS-CoV-2).
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
C07C 229/58 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé avec des groupes amino et carboxyle liés en position ortho ayant l'atome d'azote d'au moins un des groupes amino lié de plus à un atome de carbone d'un cycle aromatique à six chaînons, p. ex. acides N-phénylanthraniliques
A compact, lightweight hydraulic manipulation system used for underwater applications is disclosed. The system comprises a hybrid underwater manipulator and a hydraulic control framework comprising at least two compensating soft bladders. The system is used for general underwater work such as underwater sampling, hyperbaric welding, and marine aquaculture.
Disclosed are soft origami actuators with embedded optical waveguides and underwater manipulator applications.An underwater manipulator with a gripper is also presented, actuated with the same soft origami actuators. The main contributions of this disclosure include: 1) coupling of stretching and bending are eliminated by combing origami soft actuators and special designed optical waveguide; 2) the optical waveguide is designed such that no cladding is needed which largely reduces fabrication complexity; and 3) a new hybrid underwater manipulator is described, with redundant position feedback for accuracy and dexterous underwater applications.
Compositions and immunoassays for detecting SARS-CoV-2 antigen-specific antibodies in a biological sample are provided. The compositions are antigens from SARS-CoV-2 such as the proteins N, M, S, S1, S2', NSP1, ORF3a, ORF3b, ORF7a, ORF7b and ORF8, fused to a light emitting protein. The compositions are useful in immunoassays for detecting antibodies to the SARS-CoV-2 antigens. A preferred immunoassay is the luciferase immunoprecipitation systems (LIPS) to detect SARS-CoV-2 antigen-specific antibodies with high sensitivity and specificity. The current or present exposure or infection with SARS-CoV-2 can be detected and/or diagnosed using the disclosed compositions and methods. Typically, the presence and/or elevated amount of SARS-CoV-2 antibodies in the individual's biological sample compared to a control is indicative of current or past exposure or infection with SARS-CoV-2 as discussed herein.
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
A61P 31/14 - Antiviraux pour le traitement des virus ARN
88.
DIMMING METHOD AND CIRCUIT FOR LIGHT-EMITTING-DIODE (LED) SYSTEMS DRIVEN BY PASSIVE LED DRIVERS
This invention is related to a dimming method and a dimming circuit for light-emitting-diode (LED) assemblies driven by nominally non-dimmable passive LED drivers. An LED system usually consists of an LED driver and an LED assembly. The LED driver normally provides a current source for the LED assembly. The LED assembly consists of individual LED devices or several LED modules mounted on a heatsink. LED devices or modules can be connected in series or in parallel or a combination of both. This invention involves the combined use of a controller and circuit for providing dimming function in the LED assembly driven by a passive LED driver without closed-loop current regulation. By using one or more controllable bypass-switches across sections of the LED strings in an LED assembly, the power of one or more groups of LED devices or LED modules can be cut off in order to dim the LED system. When the voltage of LED is reduced by closing the bypass switch or switches, a uniqueness of this invention is that the per-unit increase in the output current of the passive driver must be smaller than the per-unit voltage reduction of the LED load, resulting in reduction of power consumption in the LED load for dimming purpose. The dimming control can take turns to cut off the power of different groups of LED devices or modules in different times in order to share operating burden and preserve lifetime of the LED assembly. The invention is particularly suitable for, but not restrict to, lighting applications in smart lampposts in which smart wireless communication systems are mounted on the same lampposts as the LED assemblies and dimming signals can be received wirelessly. The advantages of this invention are that the dimming function is provided in the LED assembly rather than in the LED drivers, and the dimming circuit can be linked to smart control in emerging smart lampposts.
Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 31/14 - Antiviraux pour le traitement des virus ARN
90.
PD1-BASED VACCINATION COMPOSITION AND METHODS THEREOF
Provided herein is DNA vaccine and composition comprising PD1-based TWIST1. Also provided is a method for inducing TWIST1-specific T cell response by administering a PD1-based TWIST1 vaccine. Also provided is a method for inducing TWIST1-specific T cell response by administering a PD1-based TWIST1 vaccine and an immune checkpoint inhibitor.
Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.
Live attenuated viruses for protection against the novel coronavirus Sars-CoV-2 are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza virus (LAIV), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain preferably shows spontaneous cold adaption with preference to grow at 30-33℃. The DelNS1-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2.
Live attenuated viruses for protection against the novel coronavirus which emerged in Wuhan, Hubei Province of China, designated as Sars-CoV-2 by the World Health Organization (WHO) are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza virus (LAIV), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-Sars-CoV-2-CoV2Ag. The DelNS1-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33° C. The DelNS1-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. DelNS1-Sars-CoV-2-CoV2Ag is an important strategy for making highly attenuated and immunogenic live attenuated vaccines with the ability to induce protective immunity against Sars-CoV-2.
Devices and methods related to a graphene oxide-based membrane are provided. A method comprises immersing graphene oxide-based layers in a water-based solution, stirring the water-based solution in a swirling motion until the graphene oxide-based layers each physically curve, adding a crosslinker to the water-based solution to cause the formation of saccate graphene oxide-based cells that are connected to each other via channels, and stacking the saccate graphene oxide-based cells on a substrate to form a graphene oxide-based membrane.
System and method of ultrasound imaging methodology are provided. The system and method can include directing an array to transmit sets of cascaded titled ultrasound waves towards a tissue sample, decoding reflected signals through summing, subtracting, and delay operations. The reflected signals can be reconstructed to provide a final decoded output.
Methods and compounds for preventing and/or treating Zika virus (ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
97.
Compositions and methods for broad-spectrum antiviral therapy
AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-α signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
A61P 31/20 - Antiviraux pour le traitement des virus ADN
98.
PURMORPHAMINE AS A SMALL COMPOUND POSITIVE ALLOSTERIC MODULATOR OF SECRETIN RECEPTOR FOR THE TREATMENT OF HYPERTENSION
The compositions and the use thereof for treating hypertension are provided, wherein the compositions comprise KSD179019, a derivative thereof or a pharmaceutically accceptable salt thereof. Also provided are methods to design and manufacture KSD179019 analogs and derivatives with enhanced and prolonged anti-hypertensive therapeutic efficacy.
A nanostructured composite membrane filter for rapid water purification and methods for preparing the nanostructured composite membrane filter are provided. The nanostructured composite membrane includes a silver layer having a plurality of silver functionalized nanofibers for disinfecting microorganisms of water, and a chemical modified layer having a plurality of chemical modified nanofibers for removing impurities from the water. The plurality of silver functionalized nanofibers includes a plurality of polyvinyl alcohol (PVA) nanofibers coated with polydopamine (PDA) and silver, and each of the plurality of chemical modified nanofibers includes a polymer matrix such as polyvinyl alcohol (PVA) and anionic polyelectrolytes such as poly (sodium styrenesulfonate) (PSSNa) for capturing metal ions of the water.
B01D 69/00 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication
100.
COMPOSITIONS AND METHODS FOR IMPROVING VACCINATION OF HYPORESPONSIVE INDIVIDUALS
Compositions and methods are provided that enhance the ability of low- or non-responding individuals undergoing renal replacement therapy to develop a protective antibody response following immunization. A toll-like receptor agonist is applied at or near the vaccination site and left in place for a period of time following vaccination, for example with a Hepatitis B vaccine.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
brevets
